News | Implantable Cardioverter Defibrillator (ICD) | June 10, 2022

Lower Pricing Alone Unlikely to Win Sales in the Implantable Cardioverter Defibrillators Market

The ICDs market is segmented into three categories; single chamber ICDs, dual chamber ICDs, and subcutaneous ICDs, which are used to monitor heart rhythms and deliver therapy to correct heart rates that are too fast, a condition that can lead to sudden cardiac arrest.

June 10, 2022 — Setting a lower price to enter a competitive market with established brand leaders is a common penetration pricing strategy adopted by many medical device manufacturers. However, GlobalData, a leading data and analytics company, maintains that despite the strategy’s appeal in setting a pricing floor with the potential to gain quick market share from competitors, it may not work for the implantable cardioverter defibrillators (ICDs) market.

The ICDs market is segmented into three categories; single chamber ICDs, dual chamber ICDs, and subcutaneous ICDs, which are used to monitor heart rhythms and deliver therapy to correct heart rates that are too fast, a condition that can lead to sudden cardiac arrest. Medtronic Plc is the global market leader for single chamber ICDs with a 41% market share, ahead of Biotronik with a 22% share and ahead of Abbott, and Boston Scientific.

According to GlobalData’s *global brand pricing tool, the global average selling price (ASP) of the single chamber ICDs portfolio within Medtronic and Biotronik is over $14,000 and $12,500 respectively.

Medtronic launched its most recent product, Cobalt XT, in 2021. Cobalt XT is enabled with BlueSync technology to offer connected health, including the ability for clinicians to program the device through app-based remote monitoring, thereby reducing potential exposure to COVID-19. As a premium brand in the ICD market, Medtronics average selling price (ASP) for the Cobalt XT is 35% higher than the previous model Cobalt.

Tina Deng, MSc, Principal Medical Devices Analyst at GlobalData, commented: “As pricing in the ICD market is currently set at a premium level, this indicates that a pricing strategy alone may not be effective enough in persuading surgeons to move away from competitor products. Medtronic has years of experience in the field with a good reputation, offers a high quality product, a diverse ICD portfolio and continually invests in product improvement and new product lines. These factors will be reflected in their product pricing and are clearly important considerations alongside price in their clients' decision making process.”

* GlobalData global brand pricing tool: this new tool estimates brand-level selling prices (including discounts) of key medical devices in key global geographies.

For more information: https://www.globaldata.com/media/

Related Implantable Cardioverter Defibrillator Content:

ICD Channel News

Study: New Cardiac Defibrillator Much Safer for Patients

Philips supports AHA’s efforts to raise awareness of CIED infections

 

Related Content

News | EP Lab

May 24, 2022 — Attune Medical, a pioneering medical device company with a technology platform based on temperature ...

Home May 24, 2022
Home
News | EP Lab

May 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home May 04, 2022
Home
News | EP Lab

April 27, 2022 – CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home April 27, 2022
Home
News | EP Lab

Royal Philips, a global leader in health technology, announced late-breaking results of a large-scale, real-world ...

Home April 12, 2022
Home
News | EP Lab

January 14, 2022 — Medtronic has entered into a definitive agreement to acquire Affera Inc., a Boston area-based ...

Home January 14, 2022
Home
News | EP Lab

January 13, 2022 — Abbott received U.S. Food and Drug Administration (FDA) clearance for the EnSite X EP System with ...

Home January 13, 2022
Home
News | EP Lab

January 7, 2022 — Khaldoun Tarakji, M.D., M.P.H., associate section head of cardiac electrophysiology at the Heart ...

Home January 07, 2022
Home
News | EP Lab

January 5, 2022 — Stereotaxis announced a recent publication in Frontiers in Cardiovascular Medicine titled “Atrial ...

Home January 05, 2022
Home
Feature | EP Lab

Children’s Hospital Los Angeles cardiologist Michael Silka, M.D., helped to pioneer the development of indications for ...

Home December 07, 2021
Home
News | EP Lab

November 22, 2021 — BioSig Technologies Inc., a medical technology company commercializing an innovative biomedical ...

Home November 22, 2021
Home
Subscribe Now